Selling Your Veterinary Practice to Ethos Veterinary Health: A Vet’s 2026 Guide

Key takeaways

• Ethos Veterinary Health is a US specialty and emergency veterinary hospital network — and as of 2022-2023, per public announcements at the time, Ethos is owned by NVA (National Veterinary Associates).
• Sellers receiving an Ethos-branded offer are effectively engaging with NVA’s deal team for specialty and emergency platforms. The Ethos brand has been maintained on the specialty hospitals where it was historically present; the corporate operations sit inside NVA.
• Ultimate ownership chain. Specialty practice → Ethos → NVA → JAB Holdings (the Luxembourg-based privately-held investment vehicle of the Reimann family, also owner of Krispy Kreme, Panera, Pret a Manger, and other consumer-brand holdings).
• Specialty-hospital dynamics matter more than the general-practice template in any Ethos conversation. Clinical-autonomy frameworks, referral-network integration, case-acceptance protocols, and specialty equipment-investment decisions are dimensions that don’t surface in general-practice negotiations but dominate specialty-hospital evaluations.
• The most reliable way to know what Ethos/NVA — or any major specialty buyer — would actually pay for your specific specialty platform is to run a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. Ethos/NVA is invited inside that rope on practices that fit their criteria — and when they bid against a curated group of qualified competitors, the number is reliably very different from what they would offer in a direct, single-bidder conversation.

The Ethos conversation has a structural framing question that doesn’t apply to most other US veterinary buyer conversations: who is the seller actually negotiating with? The Ethos brand has been maintained on the specialty hospitals where it was historically present, and acquisition conversations that arrive under the Ethos banner are real conversations with real Ethos personnel.

But the corporate ownership and the deal-team authority sit inside NVA following the 2022-2023 acquisition. For sellers, that means the negotiation dynamics — deal structure, integration approach, post-sale operational mechanics, the rollover-equity ownership chain — all map back to NVA’s specialty playbook rather than to a free-standing Ethos-only structure.

That mapping is the through-line of every Ethos conversation. It cuts in both directions.

Specialty sellers familiar with NVA’s institutional approach get the comfort of dealing with a long-tenured operator backed by JAB’s long-hold ownership horizon. Specialty sellers who were drawn to Ethos specifically — for the specialty-network integration and the clinical reputation — find that the actual deal mechanics they’re negotiating are NVA mechanics, even if the day-to-day specialty operations sit inside the Ethos network.

What follows is the picture I’d lay out over dinner if a vet handed me an Ethos offer and asked what to do with it. Who Ethos is now within NVA, what the post-acquisition operating model means for sellers, where the specialty-hospital negotiation surfaces actually live, and how to think about Ethos/NVA against the rest of the US specialty + emergency hospital buyer pool.

Quick facts on Ethos Veterinary Health

Ethos Veterinary Health is a US specialty and emergency veterinary hospital network with a strong clinical and operational reputation built over years of independent operation prior to the NVA acquisition. The network’s footprint concentrates on specialty + emergency platforms (advanced surgery, internal medicine, oncology, neurology, emergency and critical care, and similar specialty services) rather than general practice.

Ownership. Ethos is owned by NVA (National Veterinary Associates) per public announcements at the time of the 2022-2023 acquisition. NVA itself is owned by JAB Holdings, the Luxembourg-based privately-held investment vehicle of the Reimann family.

The ultimate ownership chain runs: Ethos → NVA → JAB Holdings. JAB’s broader portfolio includes Krispy Kreme, Panera Bread, Pret a Manger, Caribou Coffee, Peet’s Coffee, Espresso House, and Keurig Dr Pepper.

JAB is a long-term holder rather than a typical PE-fund-cycle owner — its hold periods typically run seven years or longer.

Most important practical fact. The Ethos brand has been maintained post-acquisition on the specialty hospitals where it was historically present, but the deal-team authority and the corporate operating mechanics sit inside NVA. For sellers, this means an “Ethos” offer is structurally an NVA-template offer with specialty-hospital-specific operating provisions on top.

The implication is that NVA’s specialty-hospital playbook — clinical-autonomy frameworks, referral-network integration mechanics, post-sale operational standards — applies to Ethos-branded acquisitions, not a separate Ethos-only template.

For the broader NVA institutional context — JAB’s long-hold posture, general approach to brand preservation, deal-structure variants — see our NVA buyer profile. The Ethos conversation builds on that foundation.

What Ethos actually pays for specialty veterinary hospitals in 2026

The consistent pattern we see on specialty hospital deals. When a specialty or emergency hospital receives a direct offer from any major specialty buyer — Ethos/NVA included — the offer reflects the leverage the buyer perceives. A single bidder facing no visible specialty-buyer competition has no structural reason to put forward their strongest cash percentage, tightest clinical-autonomy language, or most flexible referral-network-integration terms in the first conversation.

Inside a properly structured competitive specialty process those dimensions move, often meaningfully. The pattern holds across the specialty buyer pool — Mars-affiliated entities (BluePearl specifically for specialty + emergency), PE-backed specialty roll-ups (PetVet’s specialty footprint, others), and the broader specialty-emphasis competitors all calibrate their offers to the competitive room.

Ethos/NVA does not publish a standard price sheet for specialty hospital acquisitions. Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for specialty and emergency hospitals typically clear meaningfully higher than comparable general practice multiples — reflecting the operational complexity, capital intensity, and revenue density of specialty platforms.

The actual number for any specific specialty platform depends heavily on whether other qualified specialty bidders are at the table.

For large multi-specialty platforms (with multiple specialty services and meaningful emergency capability), deal sizes routinely scale into eight-figure-plus territory. Ethos/NVA’s capital position through the JAB-backed NVA platform supports active bidding for larger specialty platforms when the practice profile fits.

For single-specialty practices (e.g., dermatology-only, oncology-only, ophthalmology-only), the buyer pool is more concentrated than the broader specialty + emergency pool — a smaller set of specialty-emphasis platforms competes most aggressively on these acquisitions. Ethos/NVA participates when the single-specialty profile fits NVA’s broader specialty network strategy.

The cash-at-close reality

For specialty hospital transactions, the cash-at-close component typically represents the same majority-of-deal-value pattern documented across the broader major-buyer pool per 2025-2026 healthcare M&A commentary (Dechert LLP, Holland & Knight, Capstone Partners). The Ethos/NVA structure follows the broader NVA template — cash at close on the majority stake, with the remainder split among earnout, rollover or partnership equity, and occasional seller notes.

The JAB long-hold ownership through NVA matters specifically for the rollover-equity dimension. Specialty hospital rollover into NVA equity sits inside a platform whose ultimate owner has no defined exit cycle.

That changes the timing dynamics of any retained equity — the standard rollover-into-PE-platform exit mechanics (next sponsor sale, recapitalization, IPO) don’t map directly onto JAB’s long-hold posture. Specialty sellers retaining equity should negotiate explicit liquidity mechanics — defined put/call windows, formula-based buyout prices, milestone-tied liquidity events — rather than relying on a platform-level exit event that may not occur on a defined cycle.

How Ethos’s acquisition team operates

Ethos-branded acquisition outreach is led by NVA’s specialty deal team. The team’s sourcing emphasizes specialty + emergency platforms that fit NVA’s broader specialty network footprint — geographic clustering, complementary specialty mix, and operational compatibility with NVA’s existing specialty infrastructure.

Specialty acquisitions are structurally different transactions from general-practice acquisitions, and the NVA specialty team’s diligence reflects that: clinical-protocol assessment, equipment-investment due diligence, specialty case-mix analysis, referral-network compatibility, and specialty-doctor retention planning all feature more prominently than they would in a general-practice deal.

For specialty sellers, the practical implication is that the conversation moves faster and runs deeper on the operational dimensions than a general-practice conversation would — but the structural deal terms (cash, earnout, rollover, non-compete) still trace back to NVA’s broader institutional template.

How Ethos integrates the specialty hospitals it acquires

Ethos’s integration approach combines NVA’s institutional back-office consolidation with specialty-hospital-specific operating preservation.

Local brand preservation. Per NVA company materials, the platform’s general approach is local brand preservation. Ethos-branded specialty hospitals have maintained their Ethos branding, and acquired independent specialty hospitals joining the Ethos/NVA network would typically follow the local-brand-preservation default.

Specific brand handling is determined under the definitive purchase agreement.

Clinical autonomy on specialty cases. Per NVA’s broader specialty playbook, acquired specialty hospitals typically retain clinical autonomy on specialty cases, protocols, and case-acceptance criteria. Specialty-doctor compensation and incentive structures get preserved through the integration.

The institutional back-office support (HR, accounting, payroll, vendor management) and the centralized continuing-education and clinical-development resources layer in around the preserved clinical core.

Referral network integration. Acquired Ethos specialty hospitals integrate into NVA’s broader specialty referral network — including referrals from NVA general practice hospitals and other Ethos specialty hospitals across the network. The referral-network access is one of the institutional features specialty sellers commonly cite when evaluating Ethos/NVA against smaller specialty buyers.

Equipment and capital-investment infrastructure. Specialty hospitals carry high capital intensity (MRI, surgical lasers, advanced diagnostic equipment, specialty inpatient infrastructure). NVA’s institutional capital position supports continued equipment investment in acquired Ethos hospitals on a more standardized cycle than independent specialty operations typically maintain.

Doctor relationships. Selling specialty owners commonly stay on as medical director for a multi-year post-close period. Specialty-doctor retention beyond the selling owner — the staff specialists whose expertise drives the practice’s referral volume — is a critical operational dimension that deserves explicit attention in the deal terms.

Ethos/NVA’s recent activity in 2025-2026

Ethos (within NVA) is among the active US specialty + emergency hospital acquirers in 2026. Capstone Partners‘ April 2026 Pet Sector M&A Update documents continued strength in specialty hospital deal volume entering Q1 2026.

Specific acquisition counts for Ethos/NVA specifically are not publicly itemized in real time.

The post-acquisition integration of Ethos into NVA is in its third-plus year, which means the institutional integration is well-developed but ongoing. For sellers in 2026 specifically, the operational integration mechanics that affect post-close practice life have largely stabilized — though specific regional operating-structure decisions and integration timelines deserve explicit clarification in the deal terms.

Have an offer from Ethos or NVA on a specialty practice? Get a Free Practice Value Estimate — send us the offer and we’ll decompose the terms (including the specialty-specific clinical and operational provisions), identify what’s typically negotiable, and project what your specialty platform would likely clear in a structured competitive process with the broader specialty buyer pool. No upfront cost, no obligation.

How Ethos/NVA compares to the other major specialty buyers

Versus Mars Veterinary Health (BluePearl). BluePearl is the Mars-affiliated specialty + emergency hospital brand, structurally Ethos/NVA’s most direct specialty competitor. Both networks operate large specialty footprints; the key differences are sponsor structure (Mars family-owned strategic vs.

JAB-backed NVA long-hold), brand handling (BluePearl operates acquired hospitals primarily under the BluePearl brand vs. Ethos/NVA preserving local + Ethos branding), and integration philosophy.

Our Mars Veterinary Health buyer profile covers the BluePearl dimensions.

Versus PetVet Care Centers (Ares Management). PetVet operates a meaningful specialty footprint within its broader US network. The structural-default difference (Ethos/NVA’s JAB long-hold vs.

PetVet’s PE-fund cycle through Ares) affects rollover-equity dynamics. Our PetVet buyer profile covers PetVet’s institutional dimensions.

Versus VCA Animal Hospitals (specialty footprint). VCA’s specialty footprint within Mars Veterinary Health competes for general-specialty platforms. The brand-handling pattern differs — VCA’s general approach is brand consolidation under the VCA name, contrasting with Ethos/NVA’s local + Ethos brand preservation.

Our VCA buyer profile covers VCA-specific dimensions.

Versus regional specialty networks and PE-backed specialty roll-ups. The smaller specialty-emphasis buyer pool includes regional networks and specialty-focused PE-backed platforms. These competitors sometimes pay more aggressively for specialty platforms that fill specific geographic or service-line gaps in their portfolios.

The right way to compare is in a structured competitive process where all of them surface their best offers in parallel.

What to negotiate before signing with Ethos/NVA

Six priorities when negotiating with the Ethos/NVA specialty deal team.

Clinical autonomy framework (highest priority). For specialty hospitals, the clinical-decision-rights framework post-close is the dimension that most determines whether the practice continues operating as the selling owner built it. Negotiate explicit language on: case-acceptance criteria authority, clinical-protocol authority, equipment-investment authority (capital expenditure thresholds), specialty-doctor compensation-structure authority, and referral-acceptance authority.

Specialty-doctor retention provisions. The specialty hospital’s value sits substantially in the staff specialists, not just the selling owner. Negotiate retention provisions — staffing-decision authority, compensation-structure preservation, and protective provisions if NVA-platform compensation standardization changes affect the specialty team — to preserve the team that drives the practice’s referral volume.

Referral-network integration terms. Acquired Ethos hospitals integrate into NVA’s broader specialty referral network. Clarify the specifics: which NVA general practice hospitals refer into the acquired specialty practice, on what terms; whether the acquired practice retains authority to develop external referral relationships independent of the NVA network; how revenue attribution works on intra-network referrals.

Cash at close percentage. Push for higher cash percentages on the acquired stake. Specialty hospital valuations are higher than general practice, so the absolute dollars at stake in the cash-vs-contingent allocation are larger.

Rollover equity terms. If the offer includes rollover, JAB’s long-hold posture through NVA changes the standard PE-platform exit mechanics. Negotiate explicit liquidity mechanics — defined put/call windows, formula-based buyout prices, milestone-tied liquidity events — that don’t depend on a platform-level exit event.

Non-compete scope. Specialty non-competes can be more restrictive than general-practice non-competes given the smaller specialty-buyer pool in any given region. Negotiate carefully: shorter duration, tighter radius, and carve-outs for specialty modalities you might continue practicing post-employment.

The specialty-hospital-within-NVA question, in depth

For specialty sellers evaluating Ethos specifically, the central question is whether the Ethos brand-preservation-within-NVA combination produces a structurally better post-sale outcome than the alternatives.

The case for Ethos/NVA. The platform brings together NVA’s long-hold institutional ownership (no defined exit pressure on the specialty hospital’s operational decisions), the established Ethos specialty network’s referral infrastructure (built before the NVA acquisition), and NVA’s broader institutional capital position (supporting continued specialty equipment investment). For specialty sellers prioritizing operational stability and institutional scale, the combination is genuinely differentiated.

The case for alternatives. Specialty sellers prioritizing maximum clinical autonomy may find smaller specialty-focused platforms — independent specialty networks, regional roll-ups, founder-led specialty groups — preserve more practice-level autonomy than NVA’s institutional template allows. Specialty sellers prioritizing maximum cash multiple may find Mars-affiliated BluePearl, PetVet specialty, or other large institutional specialty buyers compete more aggressively on headline price under competitive pressure.

A properly run specialty-focused competitive process surfaces these alternatives across multiple bidders so the seller can compare directly on the dimensions that matter most for specialty operations.

Should I take an Ethos/NVA offer or run a competitive process?

For specialty hospital transactions, the competitive process produces leverage across all the specialty-specific operational dimensions — not just the headline number. Clinical-autonomy language, referral-network integration terms, specialty-doctor retention provisions, equipment-investment authority.

Each of these moves only under competitive pressure from other qualified specialty buyers.

Ethos/NVA participates in well-run competitive processes when invited. The Ethos-specific dimensions get sharper attention when other specialty-emphasis buyers (Mars-affiliated BluePearl, PetVet specialty, smaller specialty roll-ups) are at the table on the same practice.

What our Elite Selling System actually does

For specialty hospital transactions including Ethos/NVA, our process is structured around the recognition that specialty deals have different operational mechanics than general-practice deals.

Phase one — specialty-specific diligence preparation. We prepare the seller-side specialty diligence: clinical-case-mix analysis, specialty-revenue concentration, equipment and capital-investment history, referral-network mapping, specialty-doctor retention modeling. This deeper specialty diligence supports more substantive bids than a generic general-practice template would.

Phase two — the specialty bidder curation. From the specialty-emphasis subset of the 42-plus US veterinary consolidators TE tracks, we invite the buyers whose specialty profile genuinely competes for this specific specialty platform — Ethos/NVA, Mars-affiliated BluePearl, PetVet specialty, regional specialty networks, specialty-focused roll-ups. The right specialty mix is typically 4 to 6 bidders depending on the platform’s specialty mix and geographic position.

Phase three — the specialty term-by-term comparison. Specialty bidders return their full term sheets including the specialty-specific operational provisions. The seller sees side-by-side comparisons across clinical-autonomy frameworks, referral-network integration terms, specialty-doctor retention provisions, equipment-investment authority, and the standard economic dimensions.

The choice depends on what the specialty seller prioritizes — clinical-autonomy maximization, network-referral integration depth, headline economic terms, or specific operational philosophy alignment.

The economic result holds: specialty platforms in the qualifying revenue band that run our process consistently clear materially better total economic outcomes — typically multiple seven figures, sometimes more — than the same platform would have cleared by signing the direct Ethos/NVA term sheet without exploring the specialty field.

Closing thought

Ethos Veterinary Health within NVA represents one of the larger institutional homes for US specialty + emergency hospital sellers in 2026. The combination of JAB’s long-hold ownership through NVA, the preserved Ethos specialty network’s referral infrastructure, and NVA’s broader institutional capital position is genuinely differentiated for specialty sellers who value operational stability backed by deep institutional capital.

What separates a well-negotiated Ethos/NVA specialty outcome from a mediocre one isn’t the cash multiple — specialty hospital pricing is competitive across the major specialty buyer pool. It’s the clinical-autonomy framework, the referral-network integration terms, the specialty-doctor retention provisions, and the equipment-investment authority.

Those terms determine whether the specialty practice continues operating as the selling owner built it or shifts into the institutional template across the post-close years.

If an Ethos or NVA-specialty offer is on your desk right now, the highest-leverage move is to understand how the rest of the specialty-emphasis buyer pool would structure the same platform on different operational terms before committing. Get a Free Practice Value Estimate and we’ll lay out the specialty-specific comparison we would for a client across a dinner table.

Sources

Industry M&A research and valuation data

1. Capstone Partners. Pet Sector M&A Update — April 2026. Capstone Partners industry research.
2. Octus. Veterinary Services Roll-Up Coverage, 2025-2026. Octus credit research and industry commentary.
3. Dechert LLP. Healthcare M&A: 2025-2026 Trends and Outlook. Dechert healthcare practice publications.
4. Holland & Knight. Healthcare Private Equity 2025-2026 Commentary. Holland & Knight healthcare practice publications.
5. MB Law Firm. 2025 Healthcare M&A Trends — Joint Venture and Partnership Structures. MB Law Firm healthcare publications.

Ethos, NVA, and parent company materials

6. Ethos Veterinary Health. About Ethos and US specialty + emergency footprint. Ethos company materials, 2024-2026.
7. National Veterinary Associates (NVA). About NVA and US specialty operations. NVA company materials, 2024-2026.
8. Public announcements regarding NVA acquisition of Ethos, 2022-2023.
9. JAB Holdings. Long-hold investment posture and portfolio companies. JAB company materials.

Veterinary practice operations, benchmarks, and profession data

10. iVET360. State of the Veterinary Industry — 2026 Industry Report. iVET360 industry research.
11. American Veterinary Medical Association (AVMA). 2026 AVMA Veterinary Economic Report. AVMA economic research.